ストックスクリーナーアプリを入手
2.995
3.39%
-0.105
アフターアワーズ：
3.00
0.005
+0.17%
前日終値:
$3.10
開ける：
$3.17
24時間の取引高:
257.81K
Relative Volume:
2.40
時価総額：
$81.03M
収益：
$1.04M
当期純損益:
$-32.07M
株価収益率:
-0.4644
EPS:
-6.4491
ネットキャッシュフロー:
$-26.12M
1週間 パフォーマンス:
-4.92%
1か月 パフォーマンス:
-8.69%
6か月 パフォーマンス:
-26.23%
1年 パフォーマンス:
-47.27%
1日の値動き範囲:
$2.97
$3.1792
1週間の範囲:
$2.97
$3.34
52週間の値動き範囲:
$2.4501
$5.86
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
名前
Vistagen Therapeutics Inc
セクター
電話
650-577-3600
住所
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-07-22 | ダウングレード | Jefferies | Buy → Hold |
| 2022-07-22 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2022-07-22 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2021-05-20 | 開始されました | Robert W. Baird | Outperform |
| 2021-02-18 | 開始されました | Jefferies | Buy |
| 2021-01-04 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2018-06-27 | 開始されました | Maxim Group | Buy |
| 2018-02-08 | 繰り返されました | Chardan Capital Markets | Buy |
| 2017-03-28 | 開始されました | Maxim Group | Buy |
すべてを表示
Vistagen Therapeutics Inc (VTGN) 最新ニュース
All You Need to Know About VistaGen Therapeutics Rating Upgrade to Buy - Benzinga
All You Need to Know About VistaGen Therapeutics (VTGN) Rating Upgrade to Buy - Yahoo Finance
Mental Disorder Treatment Market Expected to Expand at a Steady - openPR
Companies Like Vistagen Therapeutics (NASDAQ:VTGN) Are In A Position To Invest In Growth - Yahoo Finance
Vistagen Therapeutics (NASDAQ:VTGN) Stock Price Crosses Below Fifty Day Moving Average of $3.52 - MarketBeat
Vistagen Therapeutics (NASDAQ:VTGN) Shares Pass Below 50 Day Moving Average of $3.52 - Defense World
Mental Disorder Treatment Market Detailed In New Research - openPR
Vistagen shareholders approve board nominees and executive pay By Investing.com - Investing.com Canada
Vistagen shareholders approve board nominees and executive pay - Investing.com
Vistagen shareholders approve board nominees and executive pay By Investing.com - Investing.com UK
Vistagen Therapeutics (NASDAQ:VTGN) Stock Price Crosses Above 50 Day Moving Average of $3.49 - Defense World
Vistagen Therapeutics (NASDAQ:VTGN) Shares Cross Above 50 Day Moving Average of $3.49 - MarketBeat
The Globe and Mail - The Globe and Mail
VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Lags Revenue Estimates - MSN
VTGN (Vistagen Therapeutics) 3-Year Revenue Growth Rate : -47.50% (As of Jun. 2024) - GuruFocus.com
VTGN (Vistagen Therapeutics) Enterprise Value : $-17.63 Mil (As of Aug. 19, 2024) - GuruFocus.com
Vistagen Therapeutics, Inc. (NASDAQ:VTGN) to Post Q2 2025 Earnings of ($0.39) Per Share, William Blair Forecasts - Defense World
VTGN (Vistagen Therapeutics) Cash-to-Debt : 54.45 (As of Jun. 2024) - GuruFocus.com
Q2 2025 EPS Estimates for Vistagen Therapeutics, Inc. Lifted by Analyst (NASDAQ:VTGN) - MarketBeat
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2025 Earnings Call Transcript - Insider Monkey
Vanguard Group Inc. Sells 41,346 Shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World
Earnings call: Vistagen advances in Phase 3 trials for SAD treatment - Investing.com Canada
Earnings call: Vistagen advances in Phase 3 trials for SAD treatment - Investing.com India
Earnings call: Vistagen advances in Phase 3 trials for SAD treatment - Investing.com
Earnings call: Vistagen advances in Phase 3 trials for SAD treatment - Investing.com UK
VTGN Stock Earnings: VistaGen Therapeutics Beats EPS, Misses Revenue for Q1 2025 - InvestorPlace
VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update - wallstreet:online
Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update - Yahoo Finance
Vistagen Therapeutics (VTGN) to Release Earnings on Tuesday - Defense World
Vistagen Therapeutics (VTGN) Scheduled to Post Quarterly Earnings on Tuesday - MarketBeat
Vistagen Therapeutics (NASDAQ:VTGN) Stock Crosses Below 50-Day Moving Average of $3.60 - MarketBeat
Vistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024 - businesswire.com
Glutamate Antagonist Market Booming Worldwide With Leading Key Players -Artemis Neuroscience, VistaGen Therapeutics, Rot – Moose Gazette - Moose Gazette
Acadian Asset Management LLC Purchases New Shares in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World
3 Stocks Under $15 That Could Make You a Millionaire - Yahoo Finance
Blair William & Co. IL Lowers Stock Position in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World
3 Stocks Under $15 That Could Make You a Millionaire - InvestorPlace
Vistagen Therapeutics (NASDAQ:VTGN) Stock Price Crosses Above 50 Day Moving Average of $3.79 - Defense World
Vistagen Therapeutics (NASDAQ:VTGN) Shares Cross Above 50-Day Moving Average of $3.79 - MarketBeat
Vistagen Therapeutics appoints KPMG as new auditor - Investing.com India
Vistagen Therapeutics appoints KPMG as new auditor By Investing.com - Investing.com Nigeria
Palantir director Alexander Moore sells over $1m in company stock By Investing.com - Investing.com
Vistagen Therapeutics appoints KPMG as new auditor By Investing.com - Investing.com UK
Vistagen Therapeutics appoints KPMG as new auditor - Investing.com
Vistagen secures new patents for PH80 migraine treatment - Pharmaceutical Technology
Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine - Business Wire
Key Players and Trends in the Mental Disorder Treatment Market - openPR
Key Players and Trends in the Mental Disorder Treatment Market Scope 2024- 2031 Business Overview, Leading ... - openPR
Vistagen Awarded Mental Health America's Platinum Bell Seal for Workplace Mental Health for the Second ... - Yahoo Finance
VistaGen & EverInsight Enter Strategic Collaboration To Develop And Commercialize PH94B - Reuters
Vistagen Therapeutics Inc (VTGN) 財務データ
収益
当期純利益
現金流量
EPS
0.87%
1.31%
大文字化:
|
ボリューム (24 時間):